Get startedLog in
    Picture of H Lundbeck A/S logo

    HLUN A — H Lundbeck A/S News Story

    0.000.00%
    dk flag iconLast trade - 00:00
    HealthcareBalancedLarge CapNeutral
    All News

    Brief: Otsuka And Lundbeck Receive Complete Response Letter From U.S. FDA For SNDA Of Rexulti® (Brexpiprazole) In Combination With Sertraline For The Treatment Of Adults With PTSD

    Picture of H Lundbeck A/S logoH Lundbeck A/S
    20/09/2025 07:04
    Sept 20 (Reuters) - H Lundbeck A/S HLUNa.CO and Otsuka 4578.T:

OTSUKA AND LUNDBECK RECEIVE COMPLETE RESPONSE LETTER FROM U.S. FDA FOR SNDA OF REXULTI® (BREXPIPRAZOLE) IN COMBINATION WITH SERTRALINE FOR THE TREATMENT OF ADULTS WITH PTSD

Source text: ID:nWkr7RKxzf

Further company coverage: [HLUNa.CO]

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on H Lundbeck A/S

    See all news